Merus N.V. (NASDAQ:MRUS) previous close was $25.48 while the outstanding shares total 36.21M. The firm has a beta of 0.62. MRUS’s shares traded lower over the last trading session, losing -1.02% on 05/19/21. The shares fell to a low of $23.6127 before closing at $25.22. Intraday shares traded counted 1.02 million, which was -668.69% lower than its 30-day average trading volume of 133.15K. The stock’s Relative Strength Index (RSI) is 64.58, with weekly volatility at 9.52% and ATR at 1.74. The MRUS stock’s 52-week price range has touched low of $10.18 and a $31.27 high.
Investors have identified the Biotechnology company Merus N.V. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $961.39 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Merus N.V. (MRUS) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 386.12 million total, with 52.95 million as their total liabilities.
MRUS were able to record 19.19 million as free cash flow during the 08/12/2021 quarter of the year, this saw their quarterly net cash flow reduce by 164.06 million. In cash movements, the company had a total of 19.34 million as operating cash flow.
Potential earnings growth for Merus N.V. (MRUS)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 08/12/2021 quarter of the year, Merus N.V. recorded a total of 8.35 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 24.54% coming in sequential stages and their sales for the 08/12/2021 quarter reducing by -7.98%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 8.35 million trying to sell their products during the last quarter, with the result yielding a gross income of 30.14 million. This allows shareholders to hold on to 36.21M with the recently reported earning now reading -0.28 cents per share. This is a figure that compared to analyst’s prediction for their 08/12/2021 (-0.28 cents a share).
Having a look at the company’s valuation, the company is expected to record -2.70 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on MRUS sounds very interesting.
Is the stock of MRUS attractive?
In related news, 10% Owner, BVF PARTNERS L P/IL bought 79,500 shares of the company’s stock in a transaction that recorded on Mar 22. The purchase was performed at an average price of 22.75, for a total value of 1,808,625. As the purchase deal closes, the 10% Owner, BVF PARTNERS L P/IL now bought 250,000 shares of the company’s stock, valued at 5,749,900. Also, 10% Owner, BVF PARTNERS L P/IL bought 844,680 shares of the company’s stock in a deal that was recorded on Jan 21. The shares were cost at an average price of 24.75 per share, with a total market value of 20,905,830. Following this completion of disposal, the 10% Owner, BVF PARTNERS L P/IL now holds 160,000 shares of the company’s stock, valued at 2,568,000. In the last 6 months, insiders have changed their ownership in shares of company stock by 9.70%.
7 out of 9 analysts covering the stock have rated it a Buy, while 2 have maintained a Hold recommendation on Merus N.V.. 0 analysts has assigned a Sell rating on the MRUS stock. The 12-month mean consensus price target for the company’s shares has been set at $27.75.